Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

February 28, 2015

Conditions
Cystic Fibrosis
Interventions
DRUG

Placebo

one dose (4 capsules) of placebo

DEVICE

Tobi Podhaler

The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use

Trial Locations (13)

10595

Novartis Investigative Site, New York

32207

Novartis Investigative Site, Jacksonville

43606

Novartis Investigative Site, Toledo

60611

Novartis Investigative Site, Chicago

73104

Novartis Investigative Site, Oklahoma City

73112

Novartis Investigative Site, Oklahoma City

77030

Novartis Investigative Site, Houston

85016

Novartis Investigative Site, Phoenix

90027

Novartis Investigative Site, Los Angeles

90806

Novartis Investigative Site, Long Beach

93003

Novartis Investigative Site, Ventura

97239

Novartis Investigative Site, Portland

20010-2120

Novartis Investigative Site, Washington D.C.

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY